Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6835.0000 -9.50 (-0.14%)
NSE Jul 11, 2025 15:31 PM
Volume: 224.0K
 

6835.00
-0.14%
Motilal Oswal
Gross margin improved ~210bp YoY (~130bp QoQ) to 62.5%. This, along with a decline in other expenditure by ~180bp (as % of sales), led to margin expansion by ~180bp YoY to 35.5%. EBITDA rose ~8% YoY (+19% QoQ) to INR3.9b (est. PAT, however, grew by just 26 May 2018 ~1% YoY to INR2.6b, mainly due to a higher tax of 34% v/s 26% in 4QFY17. For FY18, sales, EBITDA and PAT stood at INR39b (-4.
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended